LeMaitre Vascular announced the termination of its distribution agreement with Elutia, formerly known as Aziyo Biologics, for porcine patches. This agreement officially concluded on April 30, 2025. The distribution of these patches contributed $5.0 million in U.S. hospital sales for LeMaitre Vascular in 2024.
The cessation of this agreement means LeMaitre Vascular will no longer generate revenue from the distribution of Elutia's porcine patches. While the company's overall strategy emphasizes direct sales and proprietary products, the loss of this specific revenue stream will be a factor in its financial reporting moving forward. This decision aligns with the company's focus on its core, higher-margin offerings.
This strategic adjustment allows LeMaitre Vascular to streamline its product portfolio and concentrate resources on its owned and differentiated vascular devices. The impact of this termination will be reflected in future financial results, as the company moves away from this particular distribution arrangement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.